Market Overview

Biomarin Closes Added Partial Exchange of Convertible Notes Due 2017

Share:
Related BMRN
Is BioMarin Still An Outperform At This Research Firm?
BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Retrophin Soars on $245M Priority Review Voucher Sale - Analyst Blog (Zacks)

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that an additional six holders of its 1.875% Convertible Senior Subordinated Notes due 2017 have agreed to exchange $75.8 million in aggregate principle amount of the notes for approximately 3.7 million shares of the Company's common stock. This, combined with the seven holders that exchanged $139.2 million in aggregate principal amount of the notes for approximately 6.8 million shares of the Company's common stock, yields a total of $215.0 million in aggregate principal amount of the notes exchanged for approximately 10.6 million shares of common stock. The notes represented approximately 66% of the previously outstanding principal amount. Approximately $110 million of the notes remain outstanding as of March 22, 2013.

The notes converted into shares of common stock in accordance with the original terms of the notes at a conversion price of approximately $20.36 per share. The total cash payment for conversion of the $75.8 million in aggregate principal amount of the notes was $4.2 million, with $6.4 million in total interest savings from accrued and future interest payments that will no longer be required, resulting in $2.2 million in net savings to BioMarin. The total combined cash payments made for these thirteen note conversions was $12.0 million, with $18.1 million of total interest savings from accrued and future interest payments that will no longer be required, resulting in $6.1 million total net savings to BioMarin. The exchanges are exempt from registration under Section 3(a)(9) of the Securities Act of 1933.

Posted-In: News Offerings

 

Related Articles (BMRN)

Around the Web, We're Loving...